Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

Study Summary

This is a prospective, observational study designed to evaluate the long-term safety and tolerability of ADVM-022 in participants with diabetic macular edema (DME). Participants who previously participated in the INFINITY parent study and received a single unilateral intravitreal dose of ADVM-022 are eligible for enrollment upon completion of the end of study visit in the parent study.

Conditions

Diabetic Macular Edema Diabetic Retinopathy

Interventions / Drugs

ADVM-022

View on ClinicalTrials.gov ↗

Sponsor

ADVM

Adverum Biotechnologies

Ophthalmology

C53/100

Study Details

Enrollment22 participants

Primary Completion—

Lead SponsorAdverum Biotechnologies, Inc.

Data Retrieved2026-04-11 02:52:31.871692+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.